|
1
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
national cancer institute of canada clinical trials group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan A, Diamandis EP and Blasutig IM:
Strategies for discovering novel pancreatic cancer biomarkers. J
Proteomics. 81:126–134. 2013. View Article : Google Scholar :
|
|
5
|
Pliarchopoulou K and Pectasides D:
Pancreatic cancer: Current and future treatment strategies. Cancer
Treat Rev. 35:431–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato N and Goggins M: The role of
epigenetic alterations in pancreatic cancer. J Hepatobiliary
Pancreat Surg. 13:286–295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones S, Zhang X, Parsons DW, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et
al: Core signaling pathways in human pancreatic cancers revealed by
global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Logsdon CD, Simeone DM, Binkley C,
Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R and Hanash
S: Molecular profiling of pancreatic adenocarcinoma and chronic
pancreatitis identifies multiple genes differentially regulated in
pancreatic cancer. Cancer Res. 63:2649–2657. 2003.PubMed/NCBI
|
|
9
|
Wang B, Sun S and Liu Z: Analysis of
dysregulation of immune system in pancreatic cancer based on gene
expression profile. Mol Biol Rep. 41:4361–4367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kern SE: Molecular genetic alterations in
ductal pancreatic adenocarcinomas. Med Clin North Am. 84:691–695.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shin SH, Kim SC, Hong SM, Kim YH, Song KB,
Park KM and Lee YJ: Genetic alterations of K-ras, p53, c-erbB-2 and
DPC4 in pancreatic ductal adenocarcinoma and their correlation with
patient survival. Pancreas. 42:216–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fryzek JP, Garabrant DH, Schenk M, Kinnard
M, Greenson JK and Sarkar FH: The association between selected risk
factors for pancreatic cancer and the expression of p53 and K-ras
codon 12 mutations. Int J Gastrointest Cancer. 37:139–145.
2006.
|
|
13
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dorsey ER, Constantinescu R, Thompson JP,
Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM,
Schifitto G, Siderowf A and Tanner CM: Projected number of people
with Parkinson disease in the most populous nations, 2005 through
2030. Neurology. 68:384–386. 2007. View Article : Google Scholar
|
|
15
|
Delhomme N, Padioleau I, Furlong EE and
Steinmetz LM: easyRNASeq: A bioconductor package for processing
RNA-Seq data. Bioinformatics. 28:2532–2533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh B, Ronghe AM, Chatterjee A, Bhat NK
and Bhat HK: MicroRNA-93 regulates NRF2 expression and is
associated with breast carcinogenesis. Carcinogenesis.
34:1165–1172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chand Y and Alam MA: Network biology
approach for identifying key regulatory genes by expression based
study of breast cancer. Bioinformation. 8:1132–1138. 2012.
View Article : Google Scholar :
|
|
18
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc Series B Stat Methodol. 289–300.
1995.
|
|
19
|
Benjamini Y: Discovering the false
discovery rate. J R Stat Soc Series B Stat Methodol. 72:405–416.
2010. View Article : Google Scholar
|
|
20
|
Lim K and Wong L: Finding consistent
disease subnetworks using PFSNet. Bioinformatics. 30:189–196. 2014.
View Article : Google Scholar
|
|
21
|
Soh D, Dong D, Guo Y and Wong L:
Consistency, comprehensiveness, and compatibility of pathway
databases. BMC Bioinformatics. 11:4492010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelder T, van Iersel MP, Hanspers K,
Kutmon M, Conklin BR, Evelo CT and Pico AR: WikiPathways: Building
research communities on biological pathways. Nucleic Acids Res.
40(Database Issue): D1301–D1307. 2012. View Article : Google Scholar :
|
|
23
|
Kanehisa M, Goto S, Sato Y, Furumichi M
and Tanabe M: KEGG for integration and interpretation of
large-scale molecular data sets. Nucleic Acids Res. 40(Database
Issue): D109–D114. 2012. View Article : Google Scholar :
|
|
24
|
Krämer A, Green J, Pollard J Jr and
Tugendreich S: Causal analysis approaches in ingenuity pathway
analysis. Bioinformatics. 30:523–530. 2014. View Article : Google Scholar :
|
|
25
|
Hu Y, Hu Y and Liu D, Yu J and Liu D:
Screening and bioinformatics analysis of differentially expressed
genes in hyperplastic scar. Nan Fang Yi Ke Da Xue Xue Bao.
34:939–944. 2014.In Chinese. PubMed/NCBI
|
|
26
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41(Database Issue): D808–D815. 2013. View Article : Google Scholar :
|
|
27
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feldmann G, Mishra A, Bisht S, Karikari C,
Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H,
Fendrich V, et al: Cyclin-dependent kinase inhibitor Dinaciclib
(SCH727965) inhibits pancreatic cancer growth and progression in
murine xenograft models. Cancer Biol Ther. 12:598–609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hempen PM, Kurpad H, Calhoun ES, Abraham S
and Kern SE: A double missense variation of the BUB1 gene and a
defective mitotic spindle checkpoint in the pancreatic cancer cell
line Hs766T. Hum Mutat. 21:4452003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Zou M, Wen X, Gu F, Li J, Liu G,
Dong J, Deng X, Gao J, Li X, et al: Development of serum parameters
panels for the early detection of pancreatic cancer. Int J Cancer.
134:2646–2655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Renouf D and Moore M: Evolution of
systemic therapy for advanced pancreatic cancer. Expert Rev
Anticancer Ther. 10:529–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kusakai G, Suzuki A, Ogura T, Kaminishi M
and Esumi H: Strong association of ARK5 with tumor invasion and
metastasis. J Exp Clin Cancer Res. 23:263–268. 2004.PubMed/NCBI
|
|
33
|
Kokkinakis DM, Liu X and Neuner RD:
Modulation of cell cycle and gene expression in pancreatic tumor
cell lines by methionine deprivation (methionine stress):
Implications to the therapy of pancreatic adenocarcinoma. Mol
Cancer Ther. 4:1338–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Michl P, Buchholz M, Rolke M, Kunsch S,
Löhr M, McClane B, Tsukita S, Leder G, Adler G and Gress TM:
Claudin-4: A new target for pancreatic cancer treatment using
Clostridium perfringens enterotoxin. Gastroenterology. 121:678–684.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dun B, Sharma A, Xu H, Liu H, Bai S, Zeng
L and She JX: Transcriptomic changes induced by mycophenolic acid
in gastric cancer cells. Am J Transl Res. 6:28–42. 2013.PubMed/NCBI
|
|
36
|
Gong D, Pomerening JR, Myers JW,
Gustavsson C, Jones JT, Hahn AT, Meyer T and Ferrell JE Jr: Cyclin
A2 regulates nuclear-envelope breakdown and the nuclear
accumulation of cyclin B1. Curr Biol. 17:85–91. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim DH, Park SE, Kim M, Ji YI, Kang MY,
Jung EH, Ko E, Kim Y, Kim S, Shim YM and Park J: A functional
single nucleotide polymorphism at the promoter region of cyclin A2
is associated with increased risk of colon, liver and lung cancers.
Cancer. 117:4080–4091. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kokkinakis DM, Liu XY and Neuner RD:
Modulation of cell cycle and gene expression in pancreatic tumor
cell lines by methionine deprivation (methionine stress):
Implications to the therapy of pancreatic adenocarcinoma. Mol
Cancer Ther. 4:1338–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Roderick HL and Cook SJ: Ca2+
signalling checkpoints in cancer: Remodelling Ca2+ for
cancer cell proliferation and survival. Nat Rev Cancer. 8:361–375.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baselga J and Arribas J: Treating cancer's
kinase 'addiction'. Nat Med. 10:786–787. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bettencourt-Dias M, Giet R, Sinka R,
Mazumdar A, Lock WG, Balloux F, Zafiropoulos PJ, Yamaguchi S,
Winter S, Carthew RW, et al: Genome-wide survey of protein kinases
required for cell cycle progression. Nature. 432:980–987. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gaudet S, Branton D and Lue RA:
Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl
Acad Sci USA. 97:5167–5172. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Park JH, Lin ML, Nishidate T, Nakamura Y
and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein
kinase, a putative cancer/testis antigen with an oncogenic activity
in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nandi AK and Rapoport AP: Expression of
PDZ-binding kinase (PBK) is regulated by cell cycle-specific
transcription factors E2F and CREB/ATF. Leuk Res. 30:437–447. 2006.
View Article : Google Scholar
|
|
46
|
Ayllón V and O'connor R: PBK/TOPK promotes
tumour cell proliferation through p38 MAPK activity and regulation
of the DNA damage response. Oncogene. 26:3451–3461. 2007.
View Article : Google Scholar
|
|
47
|
Nandi AK, Ford T, Fleksher D, Neuman B and
Rapoport AP: Attenuation of DNA damage checkpoint by PBK, a novel
mitotic kinase, involves protein-protein interaction with tumor
suppressor p53. Biochem Biophys Res Commun. 358:181–188. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hirohashi S and Kanai Y: Cell adhesion
system and human cancer morphogenesis. Cancer Sci. 94:575–581.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saiki I: Cell adhesion molecules and
cancer metastasis. Jpn J Pharmacol. 75:215–242. 1997. View Article : Google Scholar
|
|
50
|
Gong J, Muñoz AR, Chan D, Ghosh R and
Kumar AP: STAT3 down regulates LC3 to inhibit autophagy and
pancreatic cancer cell growth. Oncotarget. 5:2529–2541. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Heukamp I, Kilian M, Gregor JI, Kiewert C,
Schimke I, Kristiansen G, Walz MK, Jacobi CA and Wenger FA: Impact
of polyunsaturated fatty acids on hepato-pancreatic prostaglandin
and leukotriene concentration in ductal pancreatic cancer-is there
a correlation to tumour growth and liver metastasis? Prostaglandins
Leukot Essent Fatty Acids. 74:223–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Aravindan S, Delma CR, Thirugnanasambandan
SS, Herman TS and Aravindan N: Anti-pancreatic cancer deliverables
from sea: First-hand evidence on the efficacy, molecular targets
and mode of action for multifarious polyphenols from five different
brown-algae. PLoS One. 8:e619772013. View Article : Google Scholar : PubMed/NCBI
|
